#novo nordisk
13 stories
GLP-1 drugs show anti-aging effects but side effects remain unclear
Weight-loss drugs reduce biological age markers, but researchers are still discovering unexpected effects on hair, nails, vision and more.
MIT Technology Review · 2m
GLP-1 lawsuits mount as serious harms remain unclear
Thousands of patients are suing GLP-1 drugmakers over blindness and pancreatitis, but weak reporting systems make it hard to know how often the drugs cause real harm.
NPR · 2m
How I Took Control of My Weight Loss Journey
A man shares how Wegovy helped him lose weight and keep it off after years of struggle.
Men's Health · 1m
Hundreds of Lawsuits Claim GLP-1s Caused Permanent Vision Loss
Hundreds of lawsuits allege GLP-1 weight-loss drugs caused permanent vision loss.
Valleynewslive · 1m
Novo CEO eyes M&A deals as weight-loss dominance slips
Novo Nordisk's turnaround plan failed to convince investors, prompting CEO Mike Doustdar to signal openness to acquisitions beyond obesity drugs.
CNBC · 2m
Lilly claims one-third of new GLP-1 pill patients
Eli Lilly CEO says Foundayo is capturing a third of new oral GLP-1 patients as the company breaks ground on a six point five billion dollar Houston manufacturing facility.
CNBC · 1m
Novo's growth plan fails to impress investors
The Danish drugmaker's strategy to diversify beyond weight-loss drugs disappoints the market as patent expiry looms.
CNBC · 1m
Eli Lilly's $1500 Target Surprises Wall Street
Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027
24/7 Wall St. · 1m
Novo Nordisk Stock Drops 7% After Growth Plan Fails to Ease Competition Fears
Novo Nordisk's stock falls 7% as its post-Wegovy growth plan fails to reassure investors about competition risks
24/7 Wall St. · 1m
CFOs Pick AI Systems That Fit Their Data Rules
Enterprise AI success now depends on data control, not just model power
Pymnts · 1m
Naveen Zutshi unlocks AI's data problem
Databricks' CIO built Genie to let any employee tap company data and build with AI.
TIME · 1m
Anthropic's wet lab tests AI biology theories in real experiments
The AI safety company is running physical biology experiments to validate its models' disease-fighting potential, raising questions about its dual focus on safety and capability.
TechCrunch · 1m
Eli Lilly's obesity bet hinges on September 30 data
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble.
24/7 Wall St. · 1m